Background and Aims-One major obstacle of hepatitis B virus (HBV) research is the lack of efficient cell culture system permissive for viral infection and replication. The aim of our study was to establish a robust HBV infection model by using hepatocyte-like cells (HLCs) derived from human pluripotent stem cells.
Introduction
Hepatitis B virus (HBV) remains a major public health threat with more than 240 million individuals chronically infected worldwide and at high risk of developing liver cirrhosis and hepatocellular carcinoma (HCC) [1, 2] . Currently, there are two classes of approved treatments: nucleos(t)ide analogs (NUC) and interferon-α (IFN-α). NUC targets viral polymerase, which limits virus replication, but cannot clear virus infection. Thus, patients need to take life-long treatment with the risk of developing drug resistance. Although IFN-α can be effective in certain situations, the response rate remains low and side effects are often difficult to tolerate. Thus there is an urgent need to develop novel antivirals to cure HBV infection [2] HBV is a small, enveloped DNA virus that targets hepatocytes. The virus infects host cells through binding to the specific receptor sodium-taurocholate cotransporting polypeptide (NTCP) [3] . After entry, viral capsid is transported to the nucleus, where the relaxed circular DNA (rcDNA) is released and converted into a covalently closed circular DNA (cccDNA) by host enzymes [4] . This cccDNA persists as a minichromosome and serves as a template for transcription of the different viral RNA transcripts. The 3.5 kb pregenomic RNA (pgRNA) is encapsidated and reverse transcribed into new rcDNA. rcDNA-containing capsids are then either enveloped and released as progeny virions or recycled back to the nucleus for cccDNA pool amplification.
Although HBV was identified more than 50 years ago [5] , many fundamental aspects of the virus remain poorly understood. This includes the molecular mechanisms of HBV entry, spreading, innate immune sensing of HBV, and signaling pathways involved in HBVinduced HCC. These gaps in knowledge are partly attributable to the lack of a cell culture system that resembles the physiological status of hepatocytes and permits efficient HBV infection, replication and dissemination. Primary human hepatocytes (PHHs) have been used for many years as a gold standard for HBV in vitro studies, but their utility is restricted by availability, donor variability, and limitation for long-term culture. Alternatively, HepaRG, a liver progenitor cell line, can be used after one month differentiation, but the low HBV infection efficiency, as well as a mixed cell phenotype (half biliary-like cells and half hepatocyte-like cells), hampers clear interpretation of hepatocyte-specific interaction with HBV [6] . Other models, such as NTCP-overexpressing hepatoma cells, are not optimal due to their transformed nature. Most importantly, virus spreading, which occurs efficiently in vivo, could not be observed with the aforementioned in vitro models.
Here, we describe a novel in vitro HBV infection model based on stem cell-derived hepatocyte-like cells (HLCs), which fully supports HBV infection for at least one month. HLCs closely resemble PHHs and highly express factors important for HBV infection and replication, making them suitable for many applications, including virus-host interaction studies and drug development in patient-derived hepatocytes. Importantly, HLCs can be maintained with a long-lasting hepatocyte-specific phenotype as compared to PHHs, which easily lose their differentiation status in vitro. Furthermore, it supports HBV spreading.
Materials and Methods

Stem cell culture
Induced pluripotent stem cells (iPSCs) SC3D cell line was generated from foreskin fibroblast (CRL-2097, ATCC, Manassas, VA, USA), and reprogrammed using STEMCCA Lentivirus Reprogramming Kits (Millipore Corp., Bedford, MA, USA). Non-colony monolayer type culture human embryonic stem cells (hESCs) H9 and iPSCs SC3D cell line have been described previously [7, 8] and were maintained on growth factor-reduced (GF(-)) Matrigel (0.4 mg/ml)(Corning, NY, USA) in mTeSR1 (StemCell Technologies, Vancouver, Canada). Cells were routinely passed 1 in 8 every 5-6 days with Accutase (Life Technologies, Frederick, USA) and reseeded with mTeSR1 medium in presence of 10 µM of Rock Inhibitor Y-27632 (Millipore, Billerica, USA) as described before [7, 8] .
HLCs differentiation
Definitive endoderm was induced using the STEMdiff™ Definitive Endoderm Kit (StemCell Technologies, Vancouver, Canada), following manufacturer's instructions. Briefly, monolayer type culture of hESCs or iPSCs were resuspended using Accutase and 2 million cells were seeded per well of 6 well plates previously coated with GF(-) Matrigel (0.125 mg/ mL). Cell monolayer was then cultured in STEMdiff Definitive Endoderm Basal medium with Supplements A and B for 1 day followed by STEMdiff Definitive Endoderm Basal medium with only Supplement B for 3 days with daily medium change. For hepatic specification, DE cells were resuspended using accutase, and seeded at a concentration of 79000 cells / cm 2 in differentiation medium (High glucose DMEM, F12, 10% KOSR, 1% Glutamine, 1% NEAA, 1% Penicillin/Streptomycin)(Life technologies, Frederick, USA) containing 100ng/ml of HGF (Peprotech, Rocky Hill, USA), 1% DMSO (Sigma Aldrich, St. Louis, USA) and 10 µM Rock Inhibitor Y-27632. After one day, the cells are cultured for 7 more days in Differentiation Medium containing 100 ng/mL of HGF and 1% DMSO, with daily medium change. Hepatoblasts are then maturated for 3 days by culturing the cells in differentiation medium containing 10 −7 M of dexamethasone (Sigma Aldrich, St. Louis, USA). Differentiated HLCs can then be maintained for one month in the WEM medium based on William's E Medium containing 10% FBS, 1% Penicillin/Streptomycin, 0.17 µM of human Insulin (Sigma Aldrich, St. Louis, USA), 10 µM of hydrocortisone 21-hemisuccinate (Sigma Aldrich, St. Louis, USA), and 1.8% DMSO, with medium changed twice per week.
Hepatocytes cultures
Cryopreserved primary human hepatocytes (PHH) from different donors (Hu1420, Hu1457, Hu8209, Hu8210) were purchased from Life Technologies Corporation (New York, USA). Cells were recovered in Hepatocyte Thaw Medium (Thermo Scientific, Waltham, USA) and plated in William's E Medium + Plating Supplements (Thermo Scientific, Waltham, USA). One day after plating, PHHs were maintained in WEM medium. Huh7-NTCP and HepG2-NTCP were maintained in DMEM plus 10% FBS, 1% NEAA, 2mM L-gutamine, 1% penicillin/streptomycin, 30 µg/mL blasticidin S HCl (Thermo Scientific, Waltham, USA). HepaRG cell culture and differentiation were performed as described [9] .
Statistical analysis
Student's unpaired two-tailed t test were performed with GraphPad Prism 5.0a (GraphPad Software, La jolla, CA, USA). Data are means ± s.d. Two-sided P values < .05 are considered significant. *P< .05, **P< .01, ***P< .001.
Results
Differentiated HLCs express hepatocyte markers and HBV proviral host factors
Different protocols have been described for differentiating hESCs and patient-derived iPSCs into hepatocyte-like cells [7, 10] . The main challenges are to obtain HLCs exhibiting a mature and homogeneous level of differentiation and maintain their differentiation status in vitro. Here, we optimized our previous method to differentiate stem cells more efficiently into a homogeneous population of mature HLCs capable of retaining their phenotype for a prolonged period of time [8] . HLCs were obtained from hESCs or iPSCs (non-colony type monolayer-adapted) through a three-step differentiation protocol (Fig. 1A) [8] . After maturation, the cells were maintained in the WEM medium. Secreted human albumin was detected after hepatic specification and dramatically increased during the hepatic maturation stage ( Supplementary Fig. 1A ). Expression of hepatocyte markers were determined by qPCR ( Supplementary Fig. 1B ) and further confirmed by immunostaining ( Supplementary  Fig. 1C ). Differentiated HLCs presented key features of human hepatocytes, but still expressed α-fetoprotein (AFP). Compared to HLCs, the differentiation of HepaRG revealed a slower process and lower expression level of these proviral factors (Supplementary Fig.  2A ).
To determine the HLCs' utility as an infection model for HBV, we first evaluated the expression of known host factors essential for HBV infection and replication in HLCs. mRNA levels of viral transcription factors RXR, HNF4α, as well as viral receptor NTCP, increased continuously in both hESCs and iPSCs derived HLCs during the differentiation process (Fig. 1B) . At the end of differentiation, immunostaining revealed that nearly 100% of the cells presented nuclear expression of RXR, HNF4α, NTCP (Fig. 1C) , while only around 50% of the differentiated HepaRG (dHepaRG) expressed albumin, NTCP and HNF4α ( Supplementary Fig. 2B ). Notably, the expression of NTCP in PHH declined following isolation and subsequent culture [3, 11] . NTCP staining of HLCs showed a ubiquitous membrane expression, though at varying levels (Fig. 1C) . HLCs differentiated from either hESCs (HLC-1 and HLC-2) or iPSCs (HLC-3, HLC-4) expressed similar levels of RXR and HNF4α, as well as higher levels of NTCP in comparison to PHHs from different donors or dHepaRG (Fig. 1D ). Immunostaining uncovered that only around 50% of dHepaRG expressed albumin, NTCP and HNF4α ( Supplementary Fig. 2B ).
Stem cell-derived HLCs support productive HBV infection
We infected hESCs-derived HLCs with HBV at a multiplicity of infection (MOI) of 300 (genome equivalents per cell), and monitored kinetics of different HBV infection markers. There was a gradual increase of cccDNA from day 0 to day 14 ( Fig. 2A) followed by an increase of total viral RNA (Fig. 2B ). The establishment of cccDNA was confirmed by Southern blot ( Supplementary Fig. 3 ). Secreted hepatitis B virus surface antigen (HBsAg) and hepatitis B virus e antigen (HBeAg) showed a similar pattern (Fig. 2C ). Extracellular HBV-DNA representing newly produced virions peaked at day 11 and thereafter remained stable (Fig. 2d) . To determine the efficiency of infection, HBsAg staining was performed. The signal was weak on day 3 post-infection but became strong on day 7. On day 11, more than 30% of the cells were strongly positive for this viral protein (Fig. 2E) . To determine the efficiency of viral infection, a highly sensitive RNAscope assay was also used to detect HBV nucleic acid 10 days post infection. As shown in Fig. 2F , a MOI 50 gave 30% HBV-positive cells while MOI 200 resulted in 60% infected cells. When MOI was increased to 1000, nearly all cells were infected. No signal was detected from uninfected cells, demonstrating the high specificity of this assay. Similar infection efficiency was achieved with iPSCsderived HLCs ( Supplementary Fig. 4A , B).
To confirm viral infection, HBV-infected HLCs were treated with three known antivirals targeting different steps of viral infection. As expected, Myrcludex B, an entry inhibitor [12] , blocked all HBV infection markers, while entecavir (ETV), a reverse-transcription (RT) inhibitor, inhibited mainly HBV-DNA [13] . IFN-α affected all HBV markers due to its multi-functional antiviral properties ( Supplementary Fig. 4C ).
To test the involvement of known HBV host factors in our model, we used siRNA to knock down NTCP and APOBEC3A. Different transfection reagents were tested on HLCs, and RNAiMax showed the best effect with around 60% of knock-down efficiency ( Supplementary Fig. 4D ). As expected, siRNA-mediated knock-down of viral receptor NTCP prevented efficient HBV infection, while knock-down of the antiviral factor APOBEC3A [14, 15] led to increased viral replication ( Supplementary Fig. 4E, Fig. 2G ). These findings indicate that HLCs is a suitable model to study HBV-cell interactions.
Next, we evaluated the infectivity of viral particles produced from HBV-infected HLCs. We concentrated supernatant from infected HLCs by CsCl ultracentrifugation and observed distinct peaks of HBsAg and HBV-DNA in the gradient, which is consistent with the gradient profile of HBV serum samples ( Supplementary Fig. 4F ). Electron microscopy revealed the presence of 42-nm Dane particles, 22-nm spherical and filamentous subviral particles produced by the infected cells (Fig. 2H) . Infection of fresh HLCs with concentrated supernatant led to production and secretion of extracellular HBV-DNA and viral antigens ( Supplementary Fig. 4G ). Establishment of infection was also confirmed by HBsAg staining (Supplementary Fig. 4H ). Taken together, these data indicate that HLCs support productive HBV infection.
HLCs support long-term HBV infection
Previous studies show that PHHs can maintain HBV infection and replication for only 5 to 10 days [16] . This short window hinders longer-term studies. Their loss of hepatocytespecific functionality, after isolation from their in vivo microenvironment, including a rapid decrease of NTCP expression, probably contributes to the loss of HBV susceptibility over time [17] .
To evaluate whether HLCs can maintain their differentiation state longer, we compared gene expression of HLCs and PHHs side-by-side after maturation or plating, respectively. Consistent with previous studies [18] , PHHs lost differentiated gene expression within 10 days after in vitro culture (Fig. 3A) . In contrast, HLCs maintained high levels of proviral factors NTCP, RXR and HNF4α for a longer period of time, which only slightly decreased after three weeks following maturation (Fig. 3A) . Immunostaining revealed that although 90% of HLCs lost albumin expression after 30 days, only 50% of HLCs reduced their NTCP expression (Fig. 3B) . To assess how long we could maintain HBV infection in our model, we monitored the infected HLCs cultures for 48 days. There was a gradual decrease of albumin production (Fig. 3C ) and HBV replication (Fig. 3D ) after 20 to 24 days. Interestingly, intracellular HBV-RNA showed a similar decreasing pattern but the cccDNA remained relatively stable, suggesting that the attenuation of HBV infection might be due to the loss of viral transcription factors (Fig. 3E) . Overall, HLCs can support efficient HBV infection and replication for at least four weeks with levels slowly decreasing after day 24. To evaluate whether HLCs are still suitable for HBV infection 30 days after maturation, HLCs were infected with cell culture derived HBV (HBVcc) at a MOI 300. Even though viral replication markers were lower than infection directly after maturation, the increasing viral antigens and HBV-DNA indicated a successful infection (Fig. 3F) . Together, our results showed that the HLCs can maintain their hepatic differentiation state longer than the PHHs, which makes it a useful tool for long-term HBV infection.
HLCs support HBV spreading
We next compared HBV replication in HLCs with three other models: HepG2-NTCP, dHepaRG and PHHs. With a MOI 300, HepG2-NTCP, PHHs and HLCs showed around 50-70 % infection efficiency, while less than 20% dHepaRG were HBV-positive as revealed by RNAscope (Fig. 4A) . To probe the details of viral replication, ETV was used to block the reverse -transcription step. ETV strongly inhibited both intracellular and extracellular HBV-DNA in all four models (Fig. 4B, Supplementary Fig. 5A ). Interestingly, viral antigens, RNA and cccDNA were also reduced by ETV in HBV-infected HLCs, while only little or no effect was seen in PHHs, HepG2-NTCP or dHepaRG cells (Fig. 4C-E, Supplementary Fig.  5B,) . Initially after infection, the cccDNA pool is derived from the rcDNA of input virus, but additional cccDNA can be generated from either newly synthesized rcDNA via capsid recycling or virus spreading to un-infected cells [19] . The relatively unchanged cccDNA levels under ETV treatment in HepG2-NTCP and dHepaRG cells suggest that their cccDNA pool was established predominantly from the input virus. Furthermore, these data suggest that viral spreading or recycling of mature capsids may be occurring in our HLC infection model.
To investigate this possibility, we used virus entry inhibitor Myrcludex B alone or together with ETV one day after HBV infection. Interestingly, Myrcludex B treatment reduced both viral antigen and cccDNA in HBV-infected HLCs and PHHs, but not HepG2-NTCP or dHepaRG cells (Fig. 4F) . When we blocked viral reinfection by Myrcludex B, ETV treatment did not further inhibit viral antigens and cccDNA levels, indicating that the expansion of cccDNA pool in this model resulted from viral spreading and not capsid recycling (Fig. 4F) . To validate this hypothesis, Myrcludex B was added at different time points of HBV-infected HLCs. As expected, Myrcludex B completely blocked HBV replication when applied together with the HBV inoculum (0-14) (Fig. 5A ). In accordance with Fig 4F, viral replication was also reduced when Myrcludex B was added on 1 day (1-14) or day 4 (4-14) after infection, indicating that Myrcludex B inhibited HBV spread (Fig.  5A) . Suppressed viral replication correlated with a reduction of the cccDNA level (Fig. 5A) .
Spreading of HBV infection has been reported in humanized mice and chimpanzees, but not in previously described in vitro models [20, 21] . In HLCs, we frequently observed clusters of HBV infected cells (Fig. 5B upper picture) . These clustered structures were reduced significantly when HBV infected HLCs were treated with viral entry inhibitor Myrcludex B one day after infection (Fig. 5B lower picture, Supplementary Fig. 6A ), indicating that NTCP-mediated viral spreading occurs in HLCs. To investigate the net amplification of HBV, we used different MOI's to infect HLCs. As expected, a high MOI (200 or 1000) resulted in a plateauing of virus replication after day 17 (Fig. 5C ), whereas a low MOI (8 or 40) led to a gradual and continuous increase of virus infection over time (Fig. 5C) .
To obtain direct evidence of viral spreading, HBV infected HLCs (donor cells) and CMFDA-labeled HLCs (acceptor cells) were co-cultured. CMFDA is a stable green dye that is retained by the cells for an extended period of time. After 3 days, HBsAg was observed within acceptor cells suggesting viral spreading (Supplementary Fig. 6B ). To exclude the possibility that CMFDA dye contaminating the donor cells and further validate the finding, GFP-lentiviral transduction was used to label the acceptor cells. Similarly, acceptor cells became HBV-positive after 7 days of co-culture as indicated by either RNAscope or HBsAg staining (Fig. 5D, Supplementary Fig. 6C ). The presence of Myrcludex B in the co-culture significantly blocked infection of the acceptor cells, supporting an NTCP-mediated viral spreading mechanism. Together, our results indicate that the HLCs support NTCP-mediated HBV spreading to some extent.
Evaluation of HLCs as a model for antiviral study
There is an urgent need for development of antivirals with novel mode-of-action to improve the treatment for chronic HBV infection. In this light, our HLCs model provides a suitable model for novel antiviral discovery as it supports the full viral life cycle and responds to known antivirals. Here we further evaluated the anti-viral activity of two compounds, Genistein and PA452, in our HLC infection model.
As productive HBV infection depends extensively on host factors, host-targeting agents would provide a novel antiviral approach to treat HBV infection. Considering the potential role of estrogen receptors in the transcription of HBV genes [22] , Genistein, a plant-derived phytoestrogen that activates estrogen receptor [23] , may be a viable antiviral agent against HBV. Unexpectedly, Genistein did not show antiviral effect on HBV-infected Huh7-NTCP or HepG2-NTCP cells (Fig. 6A ). However, when tested in HLCs (Fig. 6B) or PHHs (Fig.  6C) , Genistein significantly reduced different HBV replication markers without cytotoxicity (Supplementary Fig. 7A ). This finding indicates that intracellular signaling like estrogen receptor pathway may be impaired in hepatoma cell lines, thus making HLCs a better model for this purpose.
RXR is an important hepatocyte factor that regulates HBV transcription by activating the HBV enhancer 1 [24] . PA452 is a RXR antagonist, which triggers dissociation of RXR tetramers [25] . In HBV-infected HLCs, PA452 treatment reduced all HBV infection markers (Fig. 6D) in a dose and time dependent manner (Fig. 6E ) without cytotoxicity ( Supplementary Fig. 7B ). As expected, viral RNAs were preferentially affected, supporting the concept that PA452 blocks viral transcription by antagonizing RXR. Similar results were obtained in HBV-infected PHHs (Fig. 6F) and HepG2-NTCP cells (Fig. 6G) .
Together, our results showed that the anti-viral potential of two compounds with a novel mode-of-action against HBV highlights the utility of the HLCs infection model for drug discovery targeting the full HBV life cycle and its host dependency. This model offers a unique opportunity to discover novel antivirals that can be developed for curative treatment of HBV infection.
Discussion
HBV basic research and the development of novel antivirals have been hampered by the lack of suitable infection models. The first cell-culture model system used HBV-expressing hepatoma cell lines generated by stably transfecting HBV-DNA genomic construct [26] . Other models have been developed through delivery of viral genome by baculovirus or adenovirus vectors, resulting in productive HBV replication and formation of infected viruses [27, 28] . Although these models have been used for drug testing and resistance studies, there are significant limitations, such as the absence of viral replication from cccDNA and other crucial steps of HBV life cycle. The discovery of HepaRG cells, a liver progenitor hepatoma cell line, which supports the entire HBV life cycle, provides an important tool for HBV in vitro studies [9] . However, both hepatocyte and biliary lineages are obtained from HepaRG cell cultures after one-month of differentiation. Moreover, HBV infection rates in this model are relatively low. PHHs served as the gold standard for HBV infection experiments for many years, and yet are not used widely because of their limited availability and large donor-to-donor variations. Additionally, PHHs provide a narrow time window for experimentation and rapidly lose permissiveness for HBV infection [3, 11] .
Identification of the NTCP as a functional receptor for HBV provided opportunities for developing new model system like NTCP over-expressing hepatoma cell line [3, 29] . However, the transformed nature of hepatoma cells has altered physiological response, intracellular signaling and metabolic activities, thus making them less suitable for many applications. Recently, iPSC-derived HLCs have been described to support HBV infection [10] . However their differentiation takes 20 days and infection efficiency was very low. In the present study, we took advantage of our recently published optimized protocol [8] to differentiate non-colony type, monolayer-adapted culture of hESCs and iPSCs to HLCs in 15 days. After differentiation, the cells maintained their differentiated state and allowed HBV infection for more than 4 weeks.
Despite attempts to optimize protocols for maintaining PHHs isolated from fresh human liver tissue, PHHs can rapidly dedifferentiate in culture [18, 30, 31] . This limitation compromises their hepatocyte functionality, as well as their susceptibility to HBV infection. Previous reports suggest that dedifferentiation is caused by pro-inflammatory or proliferative response induced during PHHs isolation or subsequent in vitro culture [32, 33] . Recently, a global proteomic analysis revealed that many metabolic-associated factors are downregulated in PHHs during culture [18] . Consistent with these studies, our results demonstrated the loss of the same metabolic factors in cultured PHHs like RXR, HNF4α and NTCP, which are important for HBV infection. Notably, the dedifferentiation process occurs at a slower rate in HLCs, as high expression levels of proviral factors can be maintained for more than 3 weeks, making them a suitable model for long-term HBV infection study.
It has been demonstrated that a single HBV particle is sufficient to establish an infection and spread to all hepatocytes in the liver [21] . Due to the lack of experimental models, it is unknown whether HBV is transmitted directly from cell to cell or via infection of uninfected cells by extracellular progeny virus released from already infected cells. Similar to reports on duck hepatitis B virus (DHBV) [34] , our findings indicate that human HBV mainly spreads by newly produced and secreted viruses that favored transmission to adjacent cells in the HLCs. Why the neighboring cells rather than random cells are preferred remains unknown. One explanation is that hepatocyte polarization may be required for HBV infection [35] . Newly produced virus may be released or infect preferentially within certain regions of the hepatocyte. However, the spreading kinetics of DHBV in primary duck hepatocytes are much faster than HBV in HLCs [34] . This difference can be attributable to key biological differences between the two viruses. Although DHBV is a close relative to human HBV, it has a unique gene structure, cccDNA formation mechanism and entry receptor [4, 36] . Data from HBV infected chimeric mouse model shows that HBV spreading is slow and takes more than 6 weeks in vivo [37] . Optimizations like maturation of HLCs using 3-dimensional collagen matrices, have been shown to improve HLCs functional longevity to over 75 days [38] . This approach will allow us to monitor HBV spreading even longer in HLCs.
This HLCs model system is highly suitable for antiviral discovery and testing. In the current study, we focused on inhibitors of key host factors required for viral replication, and identified Genistein and PA452 as two potential antivirals. Future studies could exploit this model for other antiviral development and combination therapy. For example, targeting viral receptors can inhibit viral spreading or targeting tyrosyl-DNA-phosphodiesterase 2 can block cccDNA formation [39] . While single treatment may not achieve HBV eradication, combination of antivirals targeting multiple steps of viral life cycle may lead to a functional cure.
This HBV infection HLCs model offers a highly physiological model system to advance our understanding of virus-host interaction including HBV pathogenesis and immune response, as well as provide new opportunities for antiviral drug screening and development. Producing iPSCs from different individuals will allow us to further characterize virus-host interactions and disease mechanisms in the context of diverse host genetics [40] .
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